Effects of combined therapy with ezetimibe plus simvastatin after drug-eluting stent implantation in a porcine coronary restenosis model.
The aim of this study was to examine the anti-proliferative and anti-inflammatory effects of ezetimibe/simvastatin (E/S) after drug-eluting stent (DES) implantation in a porcine coronary restenosis model. Pigs were randomized into two groups in which the coronary arteries (23 pigs) had DES. Stents were deployed with oversizing (stent/artery ratio 1.3:1) in porcine coronary arteries. Fifteen pigs were taken 10/20 mg of E/S and eight pigs were not taken E/S. Histopathologic analysis was assessed at 28 days after stenting. In neointima, most inflammatory cells were lymphohistiocytes. Lymphohistiocyte count was not different between two groups (337+/-227 vs. 443+/-366 cells, P=0.292), but neointima area was significantly smaller (1.00+/-0.49 mm(2) vs. 1.69+/-0.98 mm(2), P=0.021) and percent area stenosis was significantly lower (23.3+/-10% vs. 39+/-19%, P=0.007) in E/S group compared with control group. There were no significant differences in fibrin score (1.99+/-0.79 vs. 1.81+/-0.88, P=0.49), endothelial score (1.75+/-0.66 vs. 1.80+/-0.59, P=0.79), and the percent of endothelium covered lumen (43+/-21% vs. 45+/-21%, P=0.84) between E/S group and control group. Combined therapy with ezetimibe and simvastatin inhibits neointimal hyperplasia, but does not inhibit inflammatory infiltration and arterial healing after DES implantation in a porcine coronary restenosis model.
Cho
Jung Sun
JS
Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea.
Jeong
Myung Ho
MH
Sim
Doo Sun
DS
Hong
Young Joon
YJ
Lim
Kyung Seob
KS
Kim
Jung Ha
JH
Kim
Hyoung Doo
HD
Baek
Ju Yeal
JY
Yoon
Hee Jeoung
HJ
Her
Sung-Ho
SH
Jin
Seung Won
SW
Kim
Ju Han
JH
Ahn
Youngkeun
Y
Cho
Jeong Gwan
JG
Park
Jong Chun
JC
Kang
Jung Chaee
JC
D000818:Animals; D000924:Anticholesteremic Agents / Q000008:administration & dosage; D001384:Azetidines / Q000008:administration & dosage*; D023903:Coronary Restenosis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D004195:Disease Models, Animal; D004338:Drug Combinations; D004343:Drug Implants / Q000008:administration & dosage; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D000069438:Ezetimibe; D005260:Female; D006083:Graft Occlusion, Vascular / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D019821:Simvastatin / Q000008:administration & dosage*; D013552:Swine; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D001384:Azetidines; D004338:Drug Combinations; D004343:Drug Implants; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D019821:Simvastatin; D000069438:Ezetimibe